13 Jun Dual Hormone Artificial Pancreas Reduces Nocturnal Hypoglycemia in Type 1 Diabetes
MedicalResearch.com Interview with:
Dr. Ahmad Haidar Ph.D
Division of Experimental Medicine, Department of Medicine
McGill University, Montreal, QC, Canada
Medical Research: What is the background for this study? What are the main findings?
Dr. Haidar: This is the first head-to-head-to-head comparison in outpatient setting of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional pump therapy in children and adolescents with type 1 diabetes.
The main finding is that the dual-hormone artificial pancreas seems to outperform the other two systems in reducing nocturnal hypoglycemia in camp settings when the patients are very physically active during the day.
Medical Research: What should clinicians and patients take away from your report?
Dr. Haidar: Glucagon has the potential to reduce nocturnal hypoglycemia if added to the artificial pancreas. However, this needs to be confirmed in larger and longer studies as the single-hormone artificial pancreas might be sufficient in home settings (this study was conducted at a camp, which is an environment different that home).
Medical Research: What recommendations do you have for future research as a result of this study?
Dr. Haidar: We need to conduct longer and larger day-and-night outpatient studies (our study was for only 3 nights per intervention).
Citation:
DOI: http://dx.doi.org/10.1016/S2213-8587(15)00141-2
[wysija_form id=”3″]
Dr. Ahmad Haidar Ph.D, Division of Experimental Medicine, Department of Medicine, & McGill University, Montreal, QC, Canada (2015). Dual Hormone Artificial Pancreas Reduces Nocturnal Hypoglycemia in Type 1 Diabetes
Last Updated on June 13, 2015 by Marie Benz MD FAAD